ExploreWatchlistsPricing
  1. JP-listed companies
  3. Financials
  4. Net income

(4597)

Market cap
¥10.7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Dec 31, 2025-876-54.87%
Dec 31, 2024-1,941+74.55%
Dec 31, 2023-1,112-56.36%
Dec 31, 2022-2,548+2.82%
Dec 31, 2021-2,478-39.96%
Dec 31, 2020-4,127+121.05%
Dec 31, 2019-1,867-22.91%
Dec 31, 2018-2,422+140.40%
Dec 31, 2017-1,007+112.35%
Dec 31, 2016-474-26.32%
Dec 31, 2015-644-4.90%
Dec 31, 2014-677-23.11%
Dec 31, 2013-881+50.83%
Dec 31, 2012-584

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat